Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063687 · ClinicalTrials.gov registry record · Phase 2
Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
A Phase 2 study, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00063687 is a Phase 2 study that has completed, run by Advanz Pharma. The registered enrollment target is 400 participants.
The verdict
NCT00063687, a Phase 2 study, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well as clinical outcomes (e.g., death, worsening heart failure, and hospitalization) will be assessed as a composite endpoint in this trial.
Interventions
- DRUG Oxypurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063687
The ClinicalTrials.gov registry entry for NCT00063687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advanz Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxypurinol is the first listed.
NCT00063687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063687 about?
NCT00063687 is a clinical study titled "Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure". The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well...
What is the current status of trial NCT00063687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2003-03. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00063687?
The interventions under investigation include: Oxypurinol (DRUG).
Who is sponsoring clinical trial NCT00063687?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.